<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        348-334-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VULGA 65 mg XR film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MINOCYCLINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        65
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        80.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01AA08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vulga XR is a tetracycline-class drug. Vulga XR is prescription medicine used to treat pimples and red bumps (non-nodular inflammatory lesions) that happen with moderate to severe acne vulgaris in people 12 years and older. Vulga XR is not effective for acne that is not red-looking (this means acne that is not inflammatory).</p><p>It is not known if minocycline is:</p><ul><li>Safe for use longer than 12 weeks.</li><li>Safe and effective for the treatment of infections.</li><li>Safe and effective in children under the age of 12 years.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Vulga XR</strong><br />Do not take Vulga XR if you are allergic to tetracycline class- drugs. Ask your doctor or pharmacist for a list of these medicines if you are not sure.<br /><strong>Warnings and Precautions</strong><br />Before you take Vulga XR, tell your doctor if you:</p><ul><li>Have kidney problems. Your doctor may prescribe a lower dose of medicine for you.</li><li>Have liver problems.</li><li>Have diarrhea or watery stools.</li><li>Have vision problems.</li><li>Plan to have surgery with general anesthesia.</li><li>Have any other medical conditions.</li><li>Are a male, and you and your female partner are trying to conceive a baby. You should not take Vulga XR.</li><li>Are pregnant or plan to become pregnant. Vulga XR may harm your unborn baby. Taking Vulga XR while you are pregnant may cause serious side effects on the growth of bone and teeth of your baby. Talk to your doctor before taking Vulga XR if you plan to become pregnant, or if you are already taking Vulga XR and plan to become pregnant. Stop taking Vulga XR and call your doctor right away if you become pregnant while taking Vulga XR.</li><li>Are breastfeeding or plan to breastfeed. Vulga XR passes into your milk and may harm your baby. You and your doctor should decide if you will take Vulga XR or breastfeed. You should not do both.</li></ul><p>What should you avoid while taking Vulga XR?</p><ul><li>Avoid sunlight, sunlamps, and tanning beds. Vulga XR can make your skin sensitive to the sun and the light&nbsp;from sunlamps and tanning beds. You could get severe sunburn.</li><li>Protect your skin while out in sunlight.</li><li>You should not drive or operate dangerous machinery until you know how Vulga XR affects you.<br />Vulga XR may cause you to feel dizzy or lightheaded,or have a spinning feeling (vertigo).</li></ul><p><strong>Other medicines and Vulga XR</strong><br />Tell your doctor about all the other medicines you take including prescription and nonprescription medicines, vitamins and herbal supplements. Vulga XR may affect<br />the way other medicines work, and other medicines may affect how Vulga XR works.<br />Especially tell your doctor if you take:</p><ul><li>Birth control pills. Vulga XR may make your birth control pills less effective. You could become pregnant. You should use a second form of birth control while taking Vulga XR.</li><li>A blood thinner medicine.</li><li>A penicillin antibiotic medicine. Vulga XR and penicillins should not be used together.</li><li>Antacids that contain aluminum, calcium, or magnesium or iron‐containing products.</li><li>An acne medicine that contains isotretinoin. Vulga XR and isotretinoin should not be used together.</li></ul><p>Ask your doctor or pharmacist if you are not sure if your medicine is one that is listed above.</p><p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist.</p><p><strong>Vulga XR with food</strong><br />Vulga XR can be taken with or without food. Taking Vulga XR with food may lower your chances of getting irritation or ulcers in your esophagus. Your esophagus is<br />the tube that connects your mouth to your stomach.</p><p><strong>Pregnancy and breast‐feeding</strong><br />Do not take Vulga XR if you:</p><ul><li>Are pregnant or plan to become pregnant. Vulga XR may harm your unborn baby. Taking Vulga XR while you are pregnant may cause serious side effects on the growth of bone and teeth of your baby. Talk to your doctor before taking Vulga XR if you plan to&nbsp;become pregnant, or if you are already taking Vulga<br />XR and plan to become pregnant. Stop taking Vulga XR and call your doctor right away if you become pregnant while taking Vulga XR.</li><li>Are breastfeeding or plan to breastfeed. Vulga XR passes into your milk and may harm your baby. You and your doctor should decide if you will take Vulga XR or breastfeed. You should not do both.</li></ul><p><strong>Driving and using machines</strong><br />You should not drive or operate dangerous machinery until you know how Vulga XR affects you. Vulga XR may cause you to feel dizzy or lightheaded, or have a spinning feeling (vertigo).</p><p><strong>Vulga XR contains Lactose monohydrate</strong><br />Vulga XR contains lactose monohydrate.</p><p>Each 55 mg extended‐release tablet contains 58.90 mg lactose monohydrate.</p><p>Each 65 mg extended‐release tablet contains 69.62 mg lactose monohydrate.</p><p>Each 80 mg extended‐release tablet contains 85.69 mg lactose monohydrate.</p><p>Each 105 mg extended‐release tablet contains 112.46 mg lactose monohydrate.<br />If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Take Vulga XR exactly as your doctor tells you.<br />Vulga XR can be taken with or without food. Taking Vulga XR with food may lower your chances of getting irritation or ulcers in your esophagus. Your esophagus is<br />the tube that connects your mouth to your stomach.</p><p>Swallow Vulga XR Tablets whole. Do not chew, crush, or split the tablets.</p><p><strong>If you take more Vulga XR than you should</strong><br />If you take too much Vulga XR, call your doctor or poison control center right away.<br />Your doctor may do blood tests to check you for side effects during treatment with Vulga XR.</p><p><strong>If you forget to take Vulga XR</strong><br />Skipping doses or not taking all doses of Vulga XR may:</p><ul><li>Make the treatment not work as well.</li><li>Increase the chance that the bacteria will become resistant to Vulga XR.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Minocycline may cause serious side effects, including:</p><ul><li>Harm to an unborn baby. See &ldquo;Warnings and Precautions&rdquo;</li><li>Permanent teeth discoloration. Minocycline may permanently turn a baby or child&#39;s teeth yellow‐greybrown during tooth development. Minocycline should not be used during tooth development. Tooth development happens in the last half of pregnancy, and from birth to 8 years of age. See &ldquo;Warnings and Precautions&rdquo;</li><li>&nbsp;Intestine infection (pseudomembranous colitis). Pseudomembranous colitis can happen with most antibiotics, including minocycline. Call your doctor right away if you get watery diarrhea, diarrhea that does not go away, or bloody stools.</li><li>Serious liver problems. Stop taking minocycline and call your doctor right away if you get any of the following symptoms of liver problems:</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; Loss of appetite<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; Tiredness<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; Diarrhea<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; Yellowing of your skin or the whites of your eyes<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; Unexplained bleeding<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; Confusion<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; Sleepiness</p><ul><li>Central nervous system effects. See &ldquo;What should you avoid while taking Vulga XR?&rdquo; Central nervous system effects such as light headedness, dizziness, and a spinning feeling (vertigo) may go away during&nbsp;your treatment with minocycline or if treatment is stopped.</li><li>Benign intracranial hypertension, also called pseudotumor cerebri. This is a condition where there is high pressure in the fluid around the brain. This swelling may lead to vision changes and permanent vision loss. Stop taking minocycline and tell your doctor right away if you have blurred vision, vision loss, or unusual headaches.</li><li>Immune system reactions including a lupus‐like syndrome, hepatitis, and inflammation of blood or lymph vessels (vasculitis). Using minocycline for a long time to treat acne may cause immune system reactions. Tell your doctor right away if you get a fever, rash, joint pain, or body weakness. Your doctor may do tests to check your blood for immune system reactions.</li><li>Serious rash and allergic reactions. Minocycline may cause a serious rash and allergic reactions that may affect parts of your body such as your liver, lungs, kidneys and heart. Sometimes these can lead to death.</li><li>Stop taking minocycline and get medical help right away if you have any of these symptoms:<br />-&nbsp; Skin rash, hives, sores in your mouth, or your skin blisters and peels<br />-&nbsp; Swelling of your face, eyes, lips, tongue, or throat<br />-&nbsp; Trouble swallowing or breathing<br />-&nbsp; &nbsp;Blood in your urine<br />-&nbsp; &nbsp;Fever, yellowing of the skin or the whites of your eyes, dark colored urine<br />-&nbsp; &nbsp;Pain on the right side of the stomach area (abdominal pain)<br />-&nbsp; &nbsp;Chest pain or abnormal heartbeats<br />-&nbsp; &nbsp;Swelling in your legs, ankles, and feet<br />-&nbsp; &nbsp;Darkening of your nails, skin, eyes, scars, teeth, and gums</li></ul><p><strong>The most common side effects of minocycline include:</strong></p><ul><li>&nbsp;Headache</li><li>Tiredness</li><li>&nbsp;Dizziness or spinning feeling</li><li>&nbsp;Itching</li></ul><p>Call your doctor if you have a side effect that bothers you or that does not go away. Your doctor may do tests to check you for side effects during treatment with<br />minocycline.<br />These are not all the side effects with minocycline. Ask your doctor or pharmacist for more information</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not store above 30 &deg;C.<br />Store in the original package away from moisture. Keep the container tightly closed.<br />Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.<br />Do not use this medicine if you notice any visible signs of deterioration.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will<br />help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is minocycline hydrochloride.<br />Each Vulga XR 55 mg extended‐release tablet contains 63.72 mg minocycline hydrochloride equivalent to 55 mg minocycline.<br />Each Vulga XR 65 mg extended‐release tablet contains 75.30 mg minocycline hydrochloride equivalent to 65 mg minocycline.<br />Each Vulga XR 80 mg extended‐release tablet contains 92.68 mg minocycline hydrochloride equivalent to 80 mg minocycline.<br />Each Vulga XR 105 mg extended‐release tablet contains 121.64 mg minocycline hydrochloride equivalent to 105 mg minocycline.</p><p>The other ingredients are hydroxypropyl methylcellulose, lactose monohydrate, colloidal silicon dioxide, magnesium stearate and Opadry II 85F240148 Pink (in Vulga XR 55 mg only), Opadry II 85F250081 Red (in Vulga XR 65 mg only), Opadry II 85F275021 Gray (in Vulga XR 80 mg only) and Opadry II 85F200033 Purple (in Vulga XR 105 mg only).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vulga XR 55 mg Extended‐release Tablet is a pink round-shaped concaved coated tablet, embossed with "156" on one side and "JI" on the other side in blisters.
Vulga XR 65 mg Extended‐release Tablet is a red round-shaped concaved coated tablet, embossed with "167" on one side and "JI" on the other side in blisters.
Vulga XR 80 mg Extended‐release Tablet is a gray round-shaped concaved coated tablet, embossed with "157" on one side and "JI" on the other side in blisters.
Vulga XR 105 mg Extended‐release Tablet is a purple-round shaped concaved coated tablet, embossed with "158" on one side and "JI" on the other side in blisters.

Pack size: 30 Extended‐release Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al‐Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966‐1) 4980170<br />Fax: + (966‐1) 4980187<br />e‐mail: <u>medical@jpi.com.sa</u></p><p><strong>Manufacturer</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-1) 4980170&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />Fax: + (966-1) 4980187<br />e-mail: <u>medical@jpi.com.sa</u></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/2019; version number SA2.0
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ڤولجا إكس آر هو دواء من فئة التتراسيكلين. ڤولجا إكس آر هو دواء يصرف بوصفة طبية يُستخدم لعلاج البثور والنتوءات الحمراء (التقرحات الالتهابية غير العقيدية) التي تحدث مع حب الشباب المتوسط إلى الشديد لدى الأشخاص البالغين من العمر 12 عام اً فأكثر. لا يكون ڤولجا إكس آر فعالا في علاج البثور غير الحمراء (يعني هذا البثور غير الالتهابية).</p><p>من غير المعروف ما إذا كان مينوسيكلين:</p><ul><li>آمناً للاستخدام لفترة أطول من 12 أسبوعاً.</li><li>آمناً وفعالاً في علاج العدوى.</li><li>آمناً وفعالاً&nbsp;&nbsp;للأطفال دون سن 12 عاماً.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>موانع استخدام ڤولجا إكس آر</strong><br />لا تتناول ڤولجا إكس آر إذا كنت تعاني من حساسية تجاه الأدوية من فئة التتراسيكلين. اطلب من طبيبك أو الصيدلي قائمة بهذه الأدوية إذا لم تكن متأكد اً منها.<br /><strong>الاحتياطات والتحذيرات</strong><br />قبل تناول ڤولجا إكس آر، تحدث مع طبيبك إذا:</p><ul><li dir="rtl">كنت تعاني من مشاكل في الكلى. قد يصف طبيبك جرعة أقل من الدواء لك.</li><li dir="rtl">كنت تعاني من مشاكل في الكبد.&nbsp;</li><li dir="rtl">كنت تعاني من الإسهال أو البراز المائي.&nbsp;</li><li dir="rtl">كنت تعاني من مشاكل في الرؤية.&nbsp;</li><li dir="rtl">كنت ستخضع لإجراء جراحي مع استخدام تخدير عام.&nbsp;</li><li dir="rtl">كنت تعاني من أي مشاكل صحية أخرى.&nbsp;</li><li dir="rtl">كنت ذكر اً، وتحاول أنت وشريكتك الإنجاب. يجب عليك عدم تناول ڤولجا إكس آر.</li><li dir="rtl">كنتِ حاملا أو تخططين للحمل. قد يضر ڤولجا إكس آر بجنينك. قد يتسبب&nbsp; تناول ڤولجا إكس آر أثناء الحمل في حدوث آثار جانبية خطيرة على نمو&nbsp; عظم وأسنان الجنين. استشيري طبيبك قبل تناول ڤولجا إكس آر إذا كنتِ تخططين للحمل، أو إذا كنتِ تتناولين ڤولجا إكس آر بالفعل وتخططين للحمل. توقفي عن تناول ڤولجا إكس آر واتصلي بطبيبك على الفور إذا أصبحتِ حاملا أثناء تناول ڤولجا إكس آر.</li><li dir="rtl">كنتِ تقومين بالرضاعة أو تخططين للرضاعة. يفرز ڤولجا إكس آر في&nbsp; حليب الأم وقد يضر برضيعك. يجب عليك أنتِ وطبيبك أن تقررا ما إذا كنتِ ستتناولين ڤولجا إكس آر أو تقومين بالرضاعة. ويجب عليكِ ألا تقومي بالأمرين معاً.</li></ul><p>ما الذي يجب أن تتجنبه أثناء تناول ڤولجا إكس آر؟</p><ul><li dir="rtl">تجنب أشعة الشمس، المصابيح الشمسية، وحمامات تسمير البشرة. قد&nbsp;يجعل ڤولجا إكس آر جلدك حساسا للشمس ولضوء المصابيح الشمسية وحمامات تسمير البشرة. قد تصاب بحروق شمس شديدة.</li><li dir="rtl">قم بحماية جلدك أثناء الخروج في ضوء الشمس.&nbsp;</li><li dir="rtl">لا تقم بقيادة السيارة أو تشغيل الآلات حتى تعرف كيف يؤثر ڤولجا إكس آر عليك. قد يتسبب ڤولجا إكس آر في شعورك بالدوخة أو الدوار.</li></ul><p><strong>الأدوية الأخرى و ڤولجا إكس آر</strong><br />اخبر طبيبك عن جميع الأدوية الأخرى التي تتناولها، بما في ذلك المكملات<br />العشبية والفيتامينات والأدوية الموصوفة لك والتي تصرف بوصفة طبية وبدون وصفة طبية. قد يؤثر ڤولجا إكس آر على طريقة عمل الأدوية الأخرى، وقد تؤثر الأدوية الأخرى على طريقة عمل ڤولجا إكس آر.</p><p>أخبر طبيبك خصوصا&nbsp;إذا كنت تتناول:</p><ul><li dir="rtl">حبوب منع الحمل. قد يجعل ڤولجا إكس آر حبوب منع الحمل الخاصة بكِ أقل فعالية. قد يحدث الحمل. يجب عليكِ استخدام وسيلة أخرى من وسائل منع الحمل أثناء تناول ڤولجا إكس آر.</li><li dir="rtl">دواء مرقق للدم.&nbsp;</li><li dir="rtl">مضاد حيوي يحتوي على البنسللين. يجب عدم استخدام ڤولجا إكس آر&nbsp; والبنسللين معاً.</li><li dir="rtl">مضادات الحموضة التي تحتوي على الألومنيوم، الكالسيوم أو المغنيسيوم&nbsp; أو المنتجات التي تحتوي على الحديد.</li><li dir="rtl">دواء حب الشباب الذي يحتوي على إيسوتريتنيون. يجب عدم استخدام&nbsp;ڤولجا إكس آر وإيسوتريتنيون معاً.</li></ul><p>اسأل طبيبك أو الصيدلي إذا لم تكن متأكداً ما إذا كان دواؤك هو أحد الأدوية المدرجة أعلاه.<br />كن على معرفة بالأدوية التي تتناولها. واحفظها في قائمة لتعرضها على الطبيب والصيدلي.<br /><strong>ڤولجا إكس آر مع الطعام</strong><br />يمكن تناول ڤولجا إكس آر مع الطعام أو بدونه. قد يعمل تناول ڤولجا إكس آر مع الطعام في تقليل احتمالات حدوث التهيج والقرح في المريء. المريء هو الأنبوب الذي يربط بين الفم والمعدة.</p><p><strong>الحمل والرضاعة</strong><br />لا تستخدم ڤولجا إكس آر إذا:</p><ul><li dir="rtl">كنتِ حاملا أو تخططين للحمل. قد يضر ڤولجا إكس آر بجنينك. قد يتسبب&nbsp; تناول ڤولجا إكس آر أثناء الحمل في حدوث آثار جانبية خطيرة على نمو عظم وأسنان الجنين. استشيري طبيبك قبل تناول ڤولجا إكس آر إذا كنتِ تخططين للحمل، أو إذا كنتِ تتناولين ڤولجا إكس آر بالفعل وتخططين للحمل. توقفي عن تناول ڤولجا إكس آر واتصلي بطبيبك على الفور إذا أصبحتِ حاملا أثناء تناول ڤولجا إكس آر.</li><li dir="rtl">كنتِ تقومين بالرضاعة أو تخططين للرضاعة. يفرز ڤولجا إكس آر في حليب الأم وقد يضر برضيعك. يجب عليك أنتِ وطبيبك أن تقررا ما إذا&nbsp;كنتِ ستتناولين ڤولجا إكس آر أو تقومين بالرضاعة. ويجب عليكِ ألا تقومي بالأمرين معاً.</li></ul><p><strong>تأثير ڤولجا إكس آر على القيادة واستخدام الآلات</strong><br />لا تقم بقيادة السيارة أو تشغيل الآلات حتى تعرف كيف يؤثر ڤولجا إكس آر عليك. قد يتسبب ڤولجا إكس آر في شعورك بالدوخة أو الدوار.<br /><strong>يحتوي ڤولجا إكس آر على لاكتوز أحادي الماء</strong><br />يحتوي ڤولجا إكس آر على لاكتوز أحادي الماء.</p><p>يحتوي كل قرص ممتد الإطلاق من 55 ملغم على 58.90 ملغم لاكتوز أحادي الماء.</p><p>يحتوي كل قرص ممتد الإطلاق من 65 ملغم على 69.62 ملغم لاكتوز أحادي الماء.</p><p>يحتوي كل قرص ممتد الإطلاق من 80 ملغم على 85.69 لاكتوز أحادي الماء.</p><p>يحتوي كل قرص ممتد الإطلاق من 105 ملغم على 112.46 ملغم لاكتوز أحادي الماء.<br />إذا أخبرك طبيبك بأن لديك حساسية تجاه بعض السكريات، اتصل بطبيبك قبل تناول هذا المستحضر الطبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول ڤولجا إكس آر تماما&nbsp;على النحو الذي يخبرك به الطبيب.</p><p>يمكن تناول ڤولجا إكس آر مع الطعام أو بدونه. قد يعمل تناول ڤولجا إكس آر مع الطعام في تقليل احتمالات حدوث التهيج والقرح في المريء. المريء هو الأنبوب الذي يربط بين الفم والمعدة.<br />ابتلع أقراص ڤولجا إكس آر كاملة. لا تمضغ أو تسحق أو تقسم الأقراص.</p><p><strong>إذا تناولت جرعة زائدة من ڤولجا إكس آر</strong><br />إذا تناولت جرعة زائدة من ڤولجا إكس آر، اتصل بطبيبك أو مركز مكافحة السموم على الفور.<br />قد يجري طبيبك اختبارات دم لفحص إصابتك بالآثار الجانبية أثناء العلاج&nbsp;باستخدام ڤولجا إكس آر.</p><p><strong>إذا نسيت تناول ڤولجا إكس آر</strong><br />قد يسبب تخطي الجرعات أو عدم تناول كل جرعات ڤولجا إكس آر بما يلي:</p><ul><li>التأثير السلبي على فعالية العلاج.&nbsp;</li><li>زيادة احتمال أن تصبح البكتيريا مقاومة لڤولجا إكس آر.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>يمكن أن يسبب مينوسيكلين في حدوث آثار جانبية خطيرة، منها:</p><ul><li dir="rtl">إلحاق الضرر بالجنين. انظر في قسم &quot;الاحتياطات والتحذيرات&quot;&nbsp;</li><li dir="rtl">تغير لون الأسنان بشكل دائم. قد يسبب مينوسيكلين في تغير لون أسنان&nbsp;الرضيع أو الطفل بشكل دائم إلى الأصفر-الرمادي-البني أثناء نمو&nbsp;الأسنان. يجب عدم استخدام مينوسيكلين أثناء نمو الأسنان. تنمو الأسنان في النصف الأخير من الحمل، ومن الولادة حتى 8 أعوام. انظر في قسم<br />&quot;الاحتياطات والتحذيرات&quot;</li><li dir="rtl">عدوى الأمعاء (التهاب القولون الغشائي الكاذب). قد يحدث التهاب&nbsp; القولون الغشائي الكاذب مع معظم المضادات الحيوية، بما في ذلك&nbsp;مينوسيكلين. اتصل بطبيبك على الفور إذا أصبت بإسهال مائي أو إسهال لا يختفي، أو براز دموي.</li><li dir="rtl">مشاكل خطيرة في الكبد. توقف عن تناول مينوسيكلين واتصل بطبيبك&nbsp; على الفور إذا أصبت بأي من الأعراض التالية التي تدل على وجود</li><li dir="rtl">مشاكل بالكبد:</li></ul><p dir="ltr">فقدان الشهية -&nbsp; &nbsp; &nbsp;&nbsp;&nbsp; &nbsp; &nbsp;<br />التعب -&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br />الإسهال -&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br />اصفرار الجلد أو اصفرار بياض العينين -&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br />نزيف بدون سبب -&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br />إرتباك -&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br />نعاس -&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><ul><li dir="rtl">تأثيرات على الجهاز العصبي المركزي. انظر في عنوان &quot; ما الذي يجب&nbsp; أن تتجنبه أثناء تناول ڤولجا إكس آر؟&quot; قد تختفي الآثار على الجهاز&nbsp;العصبي المركزي مثل الدوار والدوخة أثناء علاجك باستخدام مينوسيكلين أو في حال إيقاف العلاج.</li><li dir="rtl">ارتفاع ضغط الدم الحميد داخل القحف، يطلق عليه أيضا&nbsp;الورم الكاذب&nbsp;المخي. هي حالة يحدث فيها ضغط مرتفع في السائل الموجود حول&nbsp;الدماغ. قد يؤدي هذا التورم إلى تغيرات في الرؤية وفقدان الرؤية بشكل دائم.&nbsp;توقف عن تناول مينوسيكلين وأخبر طبيبك على الفور إذا أصبت بتشوش في الرؤية أو فقدان الرؤية أو صداع غير معتاد.</li><li dir="rtl">ردود فعل الجهاز المناعي بما في ذلك المتلازمة المشابهة للذئبة والتهاب&nbsp;الكبد، والتهاب الأوعية الدموية أو الليمفاوية (الالتهاب الوعائي). قد يسبب استخدام مينوسيكلين لفترة طويلة لعلاج البثور في ردود فعل في الجهاز المناعي. أخبر طبيبك على الفور إذا أصبت بحمى أو طفح جلدي أو ألم في المفاصل أو ضعف بالجسم. قد يقوم طبيبك بإجراء اختبارات&nbsp;لفحص دمك بحثا&nbsp;عن حدوث ردود فعل في الجهاز المناعي.</li><li dir="rtl">طفح جلدي خطير وردود فعل تحسسية. قد يسبب مينوسيكلين في حدوث&nbsp;طفح جلدي خطير وردود فعل تحسسية قد تؤثر على أجزاء من جسمك مثل الكبد والرئتين والكلى والقلب. قد تؤدي هذه الحالات أحيانا إلى الوفاة.</li><li dir="rtl">توقف عن تناول مينوسيكلين واحصل على المساعدة الطبية على الفور&nbsp; , إذا أصبت بأي من هذه الأعراض:</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; طفح جلدي أو شرى أو قرح في الفم أو وجود نفطات في الجلد&nbsp; وتقشره<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; تورم الوجه أو العينين أو الشفتين أو اللسان أو الحلق&nbsp;<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; صعوبة في البلع أو التنفس&nbsp;<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; دم في البول&nbsp;<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp;حمى، اصفرار الجلد أو اصفرار بياض العينين، بول داكن اللون&nbsp;<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; ألم في الجانب الأيمن من منطقة المعدة (ألم في البطن)<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; ألم بالصدر أو ضربات قلب غير طبيعية&nbsp;<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; تورم في الساقين والكاحلين والقدم<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- غمقان لون الأظافر والجلد والعينين والندبات والأسنان واللثة</p><p><strong>تشمل الآثار الجانبية الأكثر شيوعًا لمينوسيكلين:</strong></p><ul><li>الصداع</li><li>التعب&nbsp;</li><li>الدوخة أو الشعور بالدوار&nbsp;</li><li>الحكة&nbsp;</li></ul><p>اتصل بطبيبك إذا ظهرت عليك آثار جانبية تزعجك أو لا تختفي. قد يجري طبيبك اختبارات لفحص إصابتك بالآثار الجانبية أثناء العلاج بمينوسيكلين.</p><p>ليست هذه هي كل الآثار الجانبية المرتبطة باستخدام مينوسيكلين. استشر&nbsp;طبيبك أو الصيدلي للحصول على مزيد من المعلومات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.<br />لا يحفظ عند درجة حرارة أعلى من 30 &deg; مئوية.<br />يحفظ داخل العبوة الأصلية بعيداً عن الرطوبة. أبق العبوة محكمة الإغلاق.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.<br />لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.<br />لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية.<br />اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي هيدروكلوريد المينوسيكلين.</p><p>يحتوي كل قرص ڤولجا إكس آر 55 ملغم ممتد الإطلاق على 63.72 ملغم هيدروكلوريد المينوسيكلين يكافئ 55 ملغم مينوسيكلين.</p><p>يحتوي كل قرص ڤولجا إكس آر 65 ملغم ممتد الإطلاق على 75.30 ملغم هيدروكلوريد المينوسيكلين يكافئ 65 ملغم مينوسيكلين.</p><p>يحتوي كل قرص ڤولجا إكس آر 80 ملغم ممتد الإطلاق على 92.68 ملغم هيدروكلوريد المينوسيكلين يكافئ 80 ملغم مينوسيكلين.</p><p>يحتوي كل قرص ڤولجا إكس آر 105 ملغم ممتد الإطلاق على 121.64 ملغم هيدروكلوريد المينوسيكلين يكافئ 105 ملغم مينوسيكلين.</p><p>المواد الأخرى المستخدمة في التركيبة التصنيعية هي هيدروكسي بروبيل ميثيل السيليولوز، لاكتوز أحادي الماء، ثاني أكسيد السيليكون الغروي،<br />ستيارات المغنيسيوم وأوبادري II 85F240148 وردي (في ڤولجا إكس آر 55 ملغم فقط),<br />وأوبادري II 85F250081&nbsp;أحمر (في ڤولجا إكس آر 65 ملغم فقط)،<br />وأوبادري II 85F275021 رمادي (في ڤولجا إكس آر 80 ملغم فقط)،<br />وأوبادري II 85F200033 أرجواني (في ڤولجا إكس آر 105 ملغم فقط)،</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>قرص ڤولجا إكس آر 55 ملغم ممتد الإطلاق هو قرص مغلف ومحدب دائري الشكل وردي اللون، منقوش عليه &quot; 156 &quot; على جهة واحدة و &quot;JI&quot;&nbsp;&nbsp; على الجهة الأخرى معبأ في أشرطة.<br />قرص ڤولجا إكس آر 65 ملغم ممتد الإطلاق هو قرص مغلف ومحدب دائري الشكل أحمر اللون، منقوش عليه &quot; 167 &quot; على جهة واحدة و &quot;JI&quot; على الجهة الأخرى معبأ في أشرطة.<br />قرص ڤولجا إكس آر 80 ملغم ممتد الإطلاق هو قرص مغلف ومحدب دائري الشكل رمادي اللون، منقوش عليه &quot; 157 &quot; على جهة واحدة و &quot;JI&quot;&nbsp;على الجهة الأخرى معبأ في أشرطة.<br />قرص ڤولجا إكس آر 105 ملغم ممتد الإطلاق هو قرص مغلف ومحدب دائري الشكل أرجواني اللون، منقوش عليه &quot; 158 &quot; على جهة واحدة و &quot;JI&quot;&nbsp; على الجهة الأخرى معبأ في أشرطة.<br />حجم العبوة: 30 قرص ممتد الإطلاق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 4980170 (1-966) +<br />فاكس:&nbsp; 4980187 (1-966) +<br />البريد الإلكتروني: medical@jpi.com.sa</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 4980170 (1-966) +<br />فاكس:&nbsp; 4980187 (1-966) +<br />البريد الإلكتروني: medical@jpi.com.sa</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2019/01 رقم النسخة SA2.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vulga XR 65 mg Extended‐release Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Vulga XR 65 mg extended‐release tablet contains 75.30 mg minocycline hydrochloride equivalent to 65 mg minocycline.
Excipient with known effect: Each extended‐release tablet contains 69.62 mg lactose monohydrate.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Extended‐release Tablets.

Vulga XR 65 mg Extended‐release Tablet is a red round‐shaped concaved coated tablet, embossed with "167" on one side and "JI" on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Indication</u><br />Vulga XR is indicated to treat only inflammatory lesions of non‐nodular moderate to severe acne vulgaris in patients 12 years of age and older.&nbsp;</p><p><u>Limitations of Use</u><br />Minocycline did not demonstrate any effect on non‐inflammatory acne lesions. Safety of minocycline has not been established beyond 12 weeks of use. This formulation of minocycline has not been evaluated in the treatment of infections.<br />To reduce the development of drug‐resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, minocycline should be used only as indicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The recommended dosage of Vulga XR is approximately 1 mg/kg once daily for 12 weeks.</p><p>Higher doses have not shown to be of additional benefit in the treatment of inflammatory lesions of acne, and may be associated with more acute vestibular side effects.</p><p>The following table shows tablet strength and body weight to achieve approximately 1 mg/kg.</p><p>Table 1: Dosing Table for minocycline</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Patient&rsquo;s Weight (lbs.)</strong></p></td><td style="vertical-align:top"><p><strong>Patient&rsquo;s Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>Tablet Strength (mg)</strong></p></td><td style="vertical-align:top"><p><strong>Actual mg/kg Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>99 &ndash; 109</p></td><td style="vertical-align:top"><p>45 &ndash; 49</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>1 &ndash; 0.92</p></td></tr><tr><td style="vertical-align:top"><p>110 &ndash; 131</p></td><td style="vertical-align:top"><p>50 &ndash; 59</p></td><td style="vertical-align:top"><p>55</p></td><td style="vertical-align:top"><p>1.10 &ndash; 0.93</p></td></tr><tr><td style="vertical-align:top"><p>132 &ndash; 157</p></td><td style="vertical-align:top"><p>60 &ndash; 71</p></td><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>1.08 &ndash; 0.92</p></td></tr><tr><td style="vertical-align:top"><p>158 &ndash; 186</p></td><td style="vertical-align:top"><p>72 &ndash; 84</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>1.11 &ndash; 0.95</p></td></tr><tr><td style="vertical-align:top"><p>187 &ndash; 212</p></td><td style="vertical-align:top"><p>85 &ndash; 96</p></td><td style="vertical-align:top"><p>90</p></td><td style="vertical-align:top"><p>1.06 &ndash; 0.94</p></td></tr><tr><td style="vertical-align:top"><p>213 &ndash; 243</p></td><td style="vertical-align:top"><p>97 &ndash; 110</p></td><td style="vertical-align:top"><p>105</p></td><td style="vertical-align:top"><p>1.08 &ndash; 0.95</p></td></tr><tr><td style="vertical-align:top"><p>244 &ndash; 276</p></td><td style="vertical-align:top"><p>111 &ndash; 125</p></td><td style="vertical-align:top"><p>115</p></td><td style="vertical-align:top"><p>1.04 &ndash; 0.92</p></td></tr><tr><td style="vertical-align:top"><p>277 &ndash; 300</p></td><td style="vertical-align:top"><p>126 &ndash; 136</p></td><td style="vertical-align:top"><p>135</p></td><td style="vertical-align:top"><p>1.07 &ndash; 0.99</p></td></tr></tbody></table><p>Vulga XR Tablets may be taken with or without food. Ingestion of food along with Vulga XR may help reduce the risk of esophageal irritation and ulceration.</p><p>In patients with renal impairment, the total dosage should be decreased by either reducing the recommended individual doses and/or by extending the time intervals between doses.</p><p><u>Pediatric Use</u></p><p>Minocycline is indicated to treat only inflammatory lesions of non‐nodular moderate to severe acne vulgaris in patients 12 years and older. Safety and effectiveness in pediatric patients below the age of 12 has not been established.</p><p>Use of tetracycline‐class antibiotics below the age of 8 is not recommended due to the potential for tooth discoloration.</p><p><u>Geriatric Use</u></p><p>Clinical studies of minocycline did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Teratogenic Effects</u></p><p>1. Minocycline, like other tetracycline‐class drugs, can cause fetal harm when administered to a pregnant woman. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus.</p><p>Vulga XR should not be used during pregnancy or by individuals of either gender who are attempting to conceive a child.</p><p>2. The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy, and childhood up to the age of 8 years) may cause permanent discoloration of the teeth (yellow‐gray‐brown). This adverse reaction is more common during long‐term use of the drug but has been observed following repeated short‐term courses. Enamel hypoplasia has also been reported. Tetracycline drugs, therefore, should not be used during tooth development.</p><p>3. All tetracyclines form a stable calcium complex in any bone‐forming tissue. A decrease in fibula growth rate has been observed in premature human infants given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued.</p><p>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can cause retardation of skeletal development on the developing fetus. Evidence of embryotoxicity has been noted in animals treated early in pregnancy.</p><p><u>Pseudomembranous Colitis</u></p><p>Clostridium difficile associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including minocycline, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.</p><p>C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p><p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.</p><p><u>Hepatotoxicity</u></p><p>Post‐marketing cases of serious liver injury, including irreversible drug‐induced hepatitis and fulminant hepatic failure (sometimes fatal) have been reported with minocycline use in the treatment of acne.</p><p><u>Metabolic Effects</u></p><p>The anti‐anabolic action of the tetracyclines may cause an increase in BUN. While this is not a problem in those with normal renal function, in patients with significantly impaired function, higher serum levels of tetracycline‐ class drugs may lead to azotemia, hyperphosphatemia, and acidosis. If renal impairment exists, even usual oral or parenteral doses may lead to excessive systemic accumulations of the drug and possible liver toxicity. Under such conditions, lower than usual total doses are indicated, and if therapy is prolonged, serum level determinations of the drug may be advisable.</p><p><u>Central Nervous System Effects</u></p><p>Central nervous system side effects including light‐headedness, dizziness or vertigo have been reported with minocycline therapy. Patients who experience these symptoms should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. These symptoms may disappear during therapy and usually rapidly disappear when the drug is discontinued.</p><p><u>Benign Intracranial Hypertension</u></p><p>Pseudotumor cerebri (benign intracranial hypertension) in adults and adolescents has been associated with the use of tetracyclines. Minocycline has been reported to cause or precipitate pseudotumor cerebri, the hallmark of which is papilledema. Clinical manifestations include headache and blurred vision. Bulging fontanels have been associated with the use of tetracyclines in infants. Although signs and symptoms of pseudotumor cerebri resolve after discontinuation of treatment, the possibility for permanent sequelae such as visual loss that may be permanent or severe exists. Patients should be questioned for visual disturbances prior to initiation of treatment with tetracyclines. If visual disturbance occurs during treatment, patients should be checked for papilledema. Concomitant use of isotretinoin and minocycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri.</p><p><u>Autoimmune Syndromes</u></p><p>Tetracyclines have been associated with the development of autoimmune syndromes. The long‐term use of minocycline in the treatment of acne has been associated with drug‐induced lupus‐like syndrome, autoimmune hepatitis and vasculitis. Sporadic cases of serum sickness have presented shortly after minocycline use.</p><p>Symptoms may be manifested by fever, rash, arthralgia, and malaise. In symptomatic patients, liver function tests, ANA, CBC, and other appropriate tests should be performed to evaluate the patients. Use of all tetracycline‐class drugs should be discontinued immediately.</p><p><u>Photosensitivity</u></p><p>Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. This has been reported rarely with minocycline. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using minocycline. If patients need to be outdoors while using minocycline, they should wear loose‐fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician.</p><p><u>Serious Skin/Hypersensitivity Reaction</u></p><p>Cases of anaphylaxis, serious skin reactions (e.g. Stevens Johnson syndrome), erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported postmarketing with minocycline use in patients with acne. DRESS syndrome consists of cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, and one or more of the following visceral complications such as: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis. Fever and lymphadenopathy may be present. In some cases, death has been reported. If this syndrome is recognized, the drug should be discontinued immediately.</p><p><u>Tissue Hyperpigmentation</u></p><p>Tetracycline‐class antibiotics are known to cause hyperpigmentation. Tetracycline therapy may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity (teeth,mucosa, alveolar bone), sclerae and heart valves. Skin and oral pigmentation has been reported to occur independently of time or amount of drug administration, whereas other tissue pigmentation has been reported to occur upon prolonged administration. Skin pigmentation includes diffuse pigmentation as well as over sites of scars or injury.</p><p><u>Development of Drug‐Resistant Bacteria</u></p><p>Bacterial resistance to the tetracyclines may develop in patients using Vulga XR, therefore, the susceptibility of bacteria associated with infection should be considered in selecting antimicrobial therapy. Because of the potential for drug‐resistant bacteria to develop during the use of Vulga XR, it should be used only as indicated.</p><p><u>Superinfection</u></p><p>As with other antibiotic preparations, use of Vulga XR may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, Vulga XR should be discontinued and appropriate therapy instituted.</p><p><u>Laboratory Monitoring</u></p><p>Periodic laboratory evaluations of organ systems, including hematopoietic, renal and hepatic studies should be performed. Appropriate tests for autoimmune syndromes should be performed as indicated.</p><p><u>Patients taking Vulga XR (minocycline HCl) Extended‐release Tablets should receive the following information</u> <u>and instructions:</u></p><ul><li>Vulga XR should not be used by pregnant women or women attempting to conceive a child.</li><li>It is recommended that minocycline not be used by men who are attempting to father a child.</li><li>Patients should be advised that pseudomembranous colitis can occur with minocycline therapy. If patients develop watery or bloody stools, they should seek medical attention.</li><li>Patients should be counseled about the possibility of hepatotoxicity. Patients should seek medical advice if they experience symptoms which can include loss of appetite, tiredness, diarrhea, skin turning yellow, bleeding easily, confusion, and sleepiness.</li><li>Patients who experience central nervous system symptoms .should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. Patients should seek medical help for persistent headaches or blurred vision.</li><li>Concurrent use of tetracycline may render oral contraceptives less effective.</li><li>Autoimmune syndromes, including drug‐induced lupus‐like syndrome, autoimmune hepatitis, vasculitis and serum sickness have been observed with tetracycline‐class drugs, including minocycline. Symptoms may be manifested by arthralgia, fever, rash and malaise. Patients who experience such symptoms should be cautioned to stop the drug immediately and seek medical help.</li><li>Patients should be counseled about discoloration of skin, scars, teeth or gums that can arise from minocycline therapy.</li><li>Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines, including minocycline. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using minocycline. If patients need to be outdoors while&nbsp;using minocycline, they should wear loose‐fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician. Treatment should be discontinued at the first evidence of skin erythema.</li><li>Vulga XR should be taken exactly as directed. Skipping doses or not completing the full course of therapy may decrease the effectiveness of the current treatment course and increase the likelihood that bacteria will develop resistance and will not be treatable by other antibacterial drugs in the future.</li><li>Patients should be advised to swallow Vulga XR Tablets whole and not to chew, crush, or split the tablets.</li></ul><p><u>Vulga XR contains Lactose</u></p><p>Vulga XR contains Lactose monohydrate. Each extended‐release tablet contains 69.62 mg lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose‐galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Anticoagulants</u></p><p>Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.</p><p><u>Penicillin</u></p><p>Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline‐class drugs in conjunction with penicillin.</p><p><u>Methoxyflurane</u></p><p>The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.</p><p><u>Antacids and Iron Preparations</u></p><p>Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron‐ containing preparations.</p><p><u>Low Dose Oral Contraceptives</u></p><p>In a multi‐center study to evaluate the effect of minocycline on low dose oral contraceptives, hormone levels over one menstrual cycle with and without minocycline 1 mg/kg once‐daily were measured. Based on the results of this trial, minocycline‐related changes in estradiol, progestinic hormone, FSH and LH plasma levels, of breakthrough bleeding, or of contraceptive failure, cannot be ruled out. To avoid contraceptive failure, female patients are advised to use a second form of contraceptive during treatment with minocycline.</p><p><u>Drug/Laboratory Test Interactions</u></p><p>False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Teratogenic Effects: Pregnancy Category D</p><p>Vulga XR should not be used during pregnancy. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and stop treatment immediately.</p><p>There are no adequate and well‐controlled studies on the use of minocycline in pregnant women. Minocycline, like other tetracycline‐class drugs, crosses the placenta and may cause fetal harm when administered to a pregnant woman.</p><p>Rare spontaneous reports of congenital anomalies including limb reduction have been reported with minocycline use in pregnancy in post‐marketing experience. Only limited information is available regarding these reports; therefore, no conclusion on causal association can be established.</p><p>Minocycline induced skeletal malformations (bent limb bones) in fetuses when administered to pregnant rats and rabbits in doses of 30 mg/kg/day and 100 mg/kg/day, respectively, (resulting in approximately 3 times and 2 times, respectively, the systemic exposure to minocycline observed in patients as a result of use of minocycline). Reduced mean fetal body weight was observed in studies in which minocycline was administered to pregnant rats at a dose of 10 mg/kg/day (which resulted in approximately the same level of systemic exposure to minocycline as that observed in patients who use minocycline).</p><p>Minocycline was assessed for effects on peri‐and post‐natal development of rats in a study that involved oral administration to pregnant rats from day 6 of gestation through the period of lactation (postpartum day 20), at dosages of 5, 10, or 50 mg/kg/day. In this study, body weight gain was significantly reduced in pregnant females that received 50 mg/kg/day (resulting in approximately 2.5 times the systemic exposure to minocycline observed in patients as a result of use of minocycline). No effects of treatment on the duration of the gestation period or the number of live pups born per litter were observed. Gross external anomalies observed in F1 pups (offspring of animals that received minocycline) included reduced body size, improperly rotated forelimbs, and reduced size of extremities. No effects were observed on the physical development, behavior, learning ability, or reproduction of F1 pups, and there was no effect on gross appearance of F2 pups (offspring of F1 animals).</p><p><u>Nursing Mothers</u></p><p>Tetracycline‐class antibiotics are excreted in human milk. Because of the potential for serious adverse effects on bone and tooth development in nursing infants from the tetracycline‐class antibiotics, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Persistent headaches, blurred vision, dizziness, tinnitus and vertigo have occurred with minocycline and patients should be warned about the possible hazards of driving or operating machinery during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Clinical Trials Experience</u></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in practice.</p><p>The following table summarizes selected adverse reactions reported in clinical trials at a rate of &ge;1% for minocycline.</p><p>Table 2: Selected Treatment‐Emergent Adverse Reactions in at least 1% of Clinical Trial Subjects</p><table border="1" cellspacing="0" cellpadding="0" style="width:765px"><tbody><tr><td style="vertical-align:top; width:261px"><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top; width:240px"><p style="text-align:center"><strong>Minocycline (1 mg/kg)</strong></p><p style="text-align:center"><strong>N = 674</strong></p><p style="text-align:center"><strong>(%)</strong></p></td><td style="vertical-align:top; width:263px"><p style="text-align:center"><strong>PLACEBO N = 364 (%)</strong></p></td></tr><tr><td style="vertical-align:top; width:261px"><p><em>At least one treatment</em></p><p><em>emergent event</em></p></td><td style="vertical-align:top; width:240px"><p style="text-align:center"><em>379 (56)</em></p></td><td style="vertical-align:top; width:263px"><p style="text-align:center"><em>197 (54)</em></p></td></tr><tr><td style="vertical-align:top; width:261px"><p>Headache</p></td><td style="vertical-align:top; width:240px"><p style="text-align:center">152 (23)</p></td><td style="vertical-align:top; width:263px"><p style="text-align:center">83 (23)</p></td></tr><tr><td style="vertical-align:top; width:261px"><p>Fatigue</p></td><td style="vertical-align:top; width:240px"><p style="text-align:center">62 (9)</p></td><td style="vertical-align:top; width:263px"><p style="text-align:center">24 (7)</p></td></tr><tr><td style="vertical-align:top; width:261px"><p>Dizziness</p></td><td style="vertical-align:top; width:240px"><p style="text-align:center">59 (9)</p></td><td style="vertical-align:top; width:263px"><p style="text-align:center">17 (5)</p></td></tr><tr><td style="vertical-align:top; width:261px"><p>Pruritus</p></td><td style="vertical-align:top; width:240px"><p style="text-align:center">31 (5)</p></td><td style="vertical-align:top; width:263px"><p style="text-align:center">16 (4)</p></td></tr><tr><td style="vertical-align:top; width:261px"><p>Malaise</p></td><td style="vertical-align:top; width:240px"><p style="text-align:center">26 (4)</p></td><td style="vertical-align:top; width:263px"><p style="text-align:center">9 (3)</p></td></tr><tr><td style="vertical-align:top; width:261px"><p>Mood alteration</p></td><td style="vertical-align:top; width:240px"><p style="text-align:center">17 (3)</p></td><td style="vertical-align:top; width:263px"><p style="text-align:center">9 (3)</p></td></tr><tr><td style="vertical-align:top; width:261px"><p>Somnolence</p></td><td style="vertical-align:top; width:240px"><p style="text-align:center">13 (2)</p></td><td style="vertical-align:top; width:263px"><p style="text-align:center">3 (1)</p></td></tr><tr><td style="vertical-align:top; width:261px"><p>Urticaria</p></td><td style="vertical-align:top; width:240px"><p style="text-align:center">10 (2)</p></td><td style="vertical-align:top; width:263px"><p style="text-align:center">1 (0)</p></td></tr><tr><td style="vertical-align:top; width:261px"><p>Tinnitus</p></td><td style="vertical-align:top; width:240px"><p style="text-align:center">10 (2)</p></td><td style="vertical-align:top; width:263px"><p style="text-align:center">5 (1)</p></td></tr><tr><td style="vertical-align:top; width:261px"><p>Arthralgia</p></td><td style="vertical-align:top; width:240px"><p style="text-align:center">9 (1)</p></td><td style="vertical-align:top; width:263px"><p style="text-align:center">2 (0)</p></td></tr><tr><td style="vertical-align:top; width:261px"><p>Vertigo</p></td><td style="vertical-align:top; width:240px"><p style="text-align:center">8 (1)</p></td><td style="vertical-align:top; width:263px"><p style="text-align:center">3 (1)</p></td></tr><tr><td style="vertical-align:top; width:261px"><p>Dry mouth</p></td><td style="vertical-align:top; width:240px"><p style="text-align:center">7 (1)</p></td><td style="vertical-align:top; width:263px"><p style="text-align:center">5 (1)</p></td></tr><tr><td style="vertical-align:top; width:261px"><p>Myalgia</p></td><td style="vertical-align:top; width:240px"><p style="text-align:center">7 (1)</p></td><td style="vertical-align:top; width:263px"><p style="text-align:center">4 (1)</p></td></tr></tbody></table><p><u>Post marketing Experience</u></p><p>Adverse reactions that have been reported with minocycline hydrochloride use in a variety of indications include:</p><ul><li>Skin and hypersensitivity reactions: fixed drug eruptions, balanitis, erythema multiforme, Stevens‐Johnson syndrome, anaphylactoid purpura, photosensitivity, pigmentation of skin and mucous membranes, hypersensitivity reactions, angioneurotic edema, anaphylaxis, DRESS syndrome .</li><li>Autoimmune conditions: polyarthralgia, pericarditis, exacerbation of systemic lupus, pulmonary infiltrates with eosinophilia, transient lupus‐like syndrome.</li><li>Central nervous system: pseudotumor cerebri, bulging fontanels in infants, decreased hearing.</li><li>Endocrine: brown‐black microscopic thyroid discoloration, abnormal thyroid function.</li><li>Oncology: thyroid cancer.</li><li>Oral: glossitis, dysphagia, tooth discoloration.</li><li>Gastrointestinal: enterocolitis, pancreatitis, hepatitis, liver failure.</li><li>Renal: reversible acute renal failure.</li><li>Hematology: hemolytic anemia, thrombocytopenia, eosinophilia.</li></ul><p>Preliminary studies suggest that use of minocycline may have deleterious effects on human spermatogenesis.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance and Drug Safety Center (NPC)</p><p>Fax: + (966‐11) 2057662</p><p>Toll free: 800‐249‐0000</p><p>Phone No.: + (966‐11) 2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</p><p>e‐mail: npc.drug@sfda.gov.sa</p><p>Website<u>: www.sfda.gov.sa/npc</u></p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Minocycline is not removed in significant quantities by hemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Minocycline hydrochloride, a semi synthetic derivative of tetracycline.</p><p><u>Mechanism of action</u></p><p>The mechanism of action of minocycline for the treatment of acne is unknown.</p><p><u>Pharmacodynamic effects</u></p><p>The pharmacodynamics of minocycline for the treatment of acne are unknown.</p><p><u>Clinical studies</u></p><p>The safety and efficacy of minocycline in the treatment of inflammatory lesions of non‐nodular moderate to severe acne vulgaris was assessed in two 12‐week, multi‐center, randomized, double‐blind, placebo‐ controlled, trials in subjects &ge;12 years. The mean age of subjects was 20 years and subjects were from the following racial groups: White (73%), Hispanic (13%), Black (11%), Asian/Pacific Islander (2%), and Other (2%).</p><p>In two efficacy and safety trials, a total of 924 subjects with non‐nodular moderate to severe acne vulgaris received minocycline or placebo for a total of 12 weeks, according to the following dose assignments.</p><p>Table 3: Clinical Studies Dosing Table</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Subject&rsquo;s Weight (lbs.)</p></td><td style="vertical-align:top"><p>Subject&rsquo;s Weight (kg)</p></td><td style="vertical-align:top"><p>Available Tablet Strength (mg)</p></td><td style="vertical-align:top"><p>Actual mg/kg Dose</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">99 &ndash; 131</p></td><td style="vertical-align:top"><p style="text-align:center">45 &ndash; 59</p></td><td style="vertical-align:top"><p style="text-align:center">45</p></td><td style="vertical-align:top"><p style="text-align:center">1 &ndash; 0.76</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">132 &ndash; 199</p></td><td style="vertical-align:top"><p style="text-align:center">60 &ndash; 90</p></td><td style="vertical-align:top"><p style="text-align:center">90</p></td><td style="vertical-align:top"><p style="text-align:center">1.5 &ndash; 1</p></td></tr><tr><td style="vertical-align:top"><p style="text-align:center">200 &ndash; 300</p></td><td style="vertical-align:top"><p style="text-align:center">91 &ndash; 136</p></td><td style="vertical-align:top"><p style="text-align:center">135</p></td><td style="vertical-align:top"><p style="text-align:center">1.48 &ndash; 0.99</p></td></tr></tbody></table><p>The two primary efficacy endpoints were:</p><p>1)&nbsp; Mean percent change in inflammatory lesion counts from Baseline to 12 weeks.</p><p>2)&nbsp;&nbsp; Percentage of subjects with an Evaluator&rsquo;s Global Severity Assessment (EGSA) of clear or almost clear at 12 weeks. Efficacy results are presented in Table 4.</p><p>Table 4: Efficacy Results at Week 12 Trial 1 Trial 2</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Trial 1</p></td><td colspan="2" style="vertical-align:top"><p>Trial 2</p></td></tr><tr><td style="vertical-align:top"><p>Minocycline (1 mg/kg)</p><p>N = 300</p></td><td style="vertical-align:top"><p>Placebo N = 151</p></td><td style="vertical-align:top"><p>Minocycline (1 mg/kg)</p><p>N = 315</p></td><td style="vertical-align:top"><p>Placebo N = 158</p></td></tr><tr><td style="vertical-align:top"><p>Mean&nbsp; &nbsp;Percent&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; improvement in&nbsp; &nbsp;inflammatory</p><p>Lesions</p></td><td style="vertical-align:top"><p>43.1%</p></td><td style="vertical-align:top"><p>31.7%</p></td><td style="vertical-align:top"><p>45.8%</p></td><td style="vertical-align:top"><p>30.8%</p></td></tr><tr><td style="vertical-align:top"><p>No. (%) of subjects clear or almost clear on the</p><p>EGSA*</p></td><td style="vertical-align:top"><p>52 (17.3%)</p></td><td style="vertical-align:top"><p>12 (7.9%)</p></td><td style="vertical-align:top"><p>50 (15.9%)</p></td><td style="vertical-align:top"><p>15 (9.5%)</p></td></tr></tbody></table><p>*Evaluator&rsquo;s global severity assessment</p><p>Minocycline did not demonstrate any effect on non‐inflammatory lesions (benefit or worsening).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Minocycline Tablets are not bioequivalent to non‐modified release minocycline products. Based on pharmacokinetic studies in healthy adults, minocycline Tablets produce a delayed Tmax at 3.5‐4.0 hours as compared to a non‐modified release reference minocycline product (Tmax at 2.25‐3 hours). At steady‐state (Day 6), the mean AUC(0&ndash;24) and Cmax were 33.32 &mu;g&times;hr/mL and 2.63 &mu;g/mL for minocycline Tablets and 46.35 &mu;g&times;hr/mL and 2.92 &mu;g/mL for minocycline capsules, respectively. These parameters are based on dose adjusted to 135 mg per day for both products.</p><p>A single‐dose, four‐way crossover study demonstrated that minocycline Tablets used in the study (45 mg, 90 mg, 135 mg) exhibited dose‐proportional pharmacokinetics. In another single‐dose, five‐way crossover pharmacokinetic study, minocycline Tablets 55 mg, 80 mg, and 105 mg were shown to be dose‐proportional to minocycline Tablets 90 mg and 135 mg.</p><p>When minocycline tablets were administered concomitantly with a meal that included dairy products, the extent and timing of absorption of minocycline did not differ from that of administration under fasting conditions.</p><p>Minocycline is lipid soluble and distributes into the skin and sebum.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis, Mutagenesis, Impairment of Fertility</u></p><ul><li>Carcinogenesis</li></ul><p>In a carcinogenicity study in which minocycline HCl was orally administered to male and female rats once daily for up to 104 weeks at dosages up to 200 mg/kg/day, minocycline HCl was associated in both genders with follicular cell tumors of the thyroid gland, including increased incidences of adenomas, carcinomas and the combined incidence of adenomas and carcinomas in males, and adenomas and the combined incidence of adenomas and carcinomas in females. In a carcinogenicity study in which minocycline HCl was orally administered to male and female mice once daily for up to 104 weeks at dosages up to 150 mg/kg/day, exposure to minocycline HCl did not result in a significantly increased incidence of neoplasms in either males or females.</p><ul><li>Mutagenesis</li></ul><p>Minocycline was not mutagenic in vitro in a bacterial reverse mutation assay (Ames test) or CHO/HGPRT mammalian cell assay in the presence or absence of metabolic activation. Minocycline was not clastogenic in vitro using human peripheral blood lymphocytes or in vivo in a mouse micronucleus test.</p><ul><li>Impairment of Fertility</li></ul><p>Male and female reproductive performance in rats was unaffected by oral doses of minocycline of up to 300 mg/kg/day (which resulted in up to approximately 40 times the level of systemic exposure to minocycline observed in patients as a result of use of minocycline). However, oral administration of 100 or 300 mg/kg/day of minocycline to male rats (resulting in approximately 15 to 40 times the level of systemic exposure to minocycline observed in patients as a result of use of minocycline) adversely affected spermatogenesis. Effects observed at 300 mg/kg/day included a reduced number of sperm cells per gram of epididymis, an apparent reduction in the percentage of sperm that were motile, and (at 100 and 300 mg/kg/day) increased numbers of morphologically abnormal sperm cells. Morphological abnormalities observed in sperm samples included absent heads, misshapen heads, and abnormal flagella.</p><p>Limited human studies suggest that minocycline may have a deleterious effect on spermatogenesis.</p><p>Minocycline should not be used by individuals&nbsp;of either gender who are attempting to conceive a child.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp; Hydroxypropyl methyl cellulose</p><p>-&nbsp;&nbsp; Lactose monohydrate</p><p>-&nbsp;&nbsp; Colloidal silicon dioxide</p><p>-&nbsp;&nbsp; Magnesium stearate</p><p>-&nbsp;&nbsp; Opadry II 85F250081 Red</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.</p><p>Store in the original package away from moisture. Keep the container tightly closed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blisters.</p><p>Pack size: 30 Extended‐release tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
 Al‐Kharj Road
P.O. BOX 106229
Riyadh 11666, Saudi Arabia 
Tel: + (966‐1) 4980170
Fax: + (966‐1) 4980187
e‐mail: medical@jpi.com.sa

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                29 January 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>